d-9

TrxR-IN-D9 is a novel inhibitor of thioredoxin reductase (TrxR).

L-838417 D9 (C-21191) is a novel deuterated subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes[1].

Febuxostat D9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Nadolol D9 is the deuterium labeled Nadolol is a blocker of non-selective beta.

Valsartan D9 is a deuterium-labeled valsartan. Valsartan is an antagonist of the angiotensin II receptor and for the treatment of high blood pressure and heart failure.

Desbutyl Lumefantrine D9, a deuterium-labeled metabolite of Lumefantrine, exhibits the incorporation of deuterium atoms.

CTP-656, a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

Miglustat-d 9 (hydrochloride), a deuterium-labeled variant of Miglustat (hydrochloride), functions as a glucosylceramide synthase inhibitor. Its primary application is in the treatment of Type I Gaucher disease (GD1) [1][2].

Choline-d9 chloride is a deuterium-labelled derivative of choline chloride for isotope tracing. Choline chloride, an essential nutrient, activates α7 nicotinic acetylcholine receptors and exhibits anti-inflammatory and analgesic properties.

2-(5-tert-Butyl-2-hydroxyphenyl)benzotriazole-d9 (2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4-(tert-butyl)phenol-d9) is the deuterated form of 2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4-(tert-butyl)phenol.

C-Met inhibitor D9 is a c-Met kinase inhibitor.

MDL-27048 is a powerful and reversible microtubule inhibitor.

Tebuconazole-d9 is intended for use as an internal standard for the quantification of tebuconazole by GC- or LC-MS. Tebuconazole is a triazole fungicide that is active against both seed and foliar fungi. It inhibits 14α-demethylase isolated from U. maydis and S. bicolor with IC50 values of 0.05 and 0.16 nM, respectively. It inhibits the androgenic effect of the androgen receptor agonist DHT (IC20 = 2.89 µM) and is cytotoxic (EC20 = 38.9 µM) in an MDA-kb2 assay. Tebuconazole (50 and 100 mg/kg per day) administered during gestation reduces testosterone levels and increases testicular levels of progesterone and 17α-hydroxyprogesterone in male rat fetuses. It has a feminizing effect on male pups and a virializing effect on female pups. When administered to rats gestationally through postnatal day 42, tebuconazole (20 and 60 mg/kg per day) leads to cell death of pyramidal cells in the CA3-4 region of the hippocampus and layer V of the cortex concomitant with impairment in learning......

Guaifenesin-d3 is intended for use as an internal standard for the quantification of guaifenesin by GC- or LC-MS. Guaifenesin is an expectorant. It inhibits production of mucin 5AC (MUC5AC), reduces mucus viscosity and elasticity, and increases the mucociliary transport rate of endogenous particles in primary human tracheobronchial epithelial cells in a concentration-dependent manner. Guaifenesin increases phenol red secretion, a marker of expectorant activity, in rats.3 Formulations containing guaifenesin have been used as expectorants in the treatment of the common cold and chronic bronchitis.

Phenylbutazone-d9 is intended for use as an internal standard for the quantification of phenylbutazone by GC- or LC-MS. Phenylbutazone is a non-steroidal anti-inflammatory drug and an inhibitor of the peroxidase activity of COX (IC50 = ~100 µM in the presence of hydrogen peroxide). It also inhibits prostaglandin I synthase (IC50 = ~25 µM in the presence of hydrogen peroxide). Phenylbutazone (2 mg/kg) reduces increases in type II collagen levels in the inflamed joints of an equine model of LPS-induced acute synovitis. Formulations containing phenylbutazone have been used in the treatment of lameness in horses.

G-33378 is a metabolite of sulfinpyrazone that inhibits human platelet cyclo-oxygenase activity.

1,3,7-Trimethyluric acid-d9 is intended for use as an internal standard for the quantification of 1,3,7-trimethyluric acid by GC- or LC-MS. 1,3,7-Trimethyluric acid is a derivative of uric acid and a metabolite of caffeine. It is formed from caffeine by the cytochrome P450 isoform CYP3A4. 1,3,7-Trimethyluric acid scavenges hydroxyl radicals in a cell-free assay and inhibits t-butyl hydroperoxide-induced lipid peroxidation by 56.5% in isolated human erythrocyte membranes.

hClpP-activator-D9 is a novel potent and species-selective activator of human ClpP (hClpP).

1-Palmitoyl-d9-2-palmitoyl-sn-glycerol serves as an internal standard for quantifying 1,2-dipalmitoyl-sn-glycerol using GC or LC-MS techniques. This diacylglycerol, featuring palmitic acid at both the sn-1 and sn-2 positions, stimulates protein kinase C (PKC) activity by 15% at a 25 μM concentration. Additionally, 1,2-dipalmitoyl-sn-glycerol encourages rapid growth in Frankia, a genus of Gram-positive bacteria.

Colfosceril miristate-d9 (DMPC-d9) is the deuterated form of Colfosceril miristate. Colfosceril miristate (DMPC) is a synthetic phospholipid employed in the study of lipid monolayers and bilayers, as well as in liposome and lipid bilayer applications.

Reserpine-d9 is a deuterated compound of Reserpine. Reserpine has a CAS number of 50-55-5. Reserpine is an alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.

BaMbuterol-d9 Hydrochloride is a deuterated compound of BaMbuterol Hydrochloride.

Brombuterol-d9 is a deuterated compound of Brombuterol.

Cimbuterol-d9 is deuterium-labeled Cimbuterol, a 12 β(2)-adrenergic agonist.